UNSPSC 51241125: Tafluprost

This classification denotes a prostaglandin analogue with the molecular formula C25H34F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O6WQ6T7G3, chemically known as isopropyl (5z)-7-{(1r,2r,3r,5s)-2-((1e)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate but generally known as tafluprost, which bears US NIH Compound Identifier 6433101. European Medicines Agency schedules Tafluprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30776.

UNSPSC 51241125 Tafluprost (Commodity) covers the procurement of tafluprost, a prostaglandin analog ophthalmic medication used in state and local health systems, correctional facilities, and public health agencies to treat elevated intraocular pressure and glaucoma. State and local governments acquire tafluprost primarily through established pharmaceutical supply chains serving public hospitals, clinics, prison medical services, and health departments. The issuing bodies soliciting under this code typically include state health departments, county hospital systems, municipal health agencies, and state and local corrections departments, which consolidate pharmaceutical purchases through individual RFQs, blanket orders, or cooperative purchasing agreements negotiated with pharmaceutical distributors and manufacturers.

The source provides no recent state and local contract opportunities under this code. Without posted solicitations in the most-recent-opportunities block, geographic concentration and representative RFQ or IFB activity cannot be characterized. Firms pursuing pharmaceutical supply contracts in state and local procurement should monitor health department and hospital system notices directly and track cooperative purchasing vehicles used by corrections and public health agencies, as individual drug procurements often post with short lead times or cycle through standing agreements rather than formal competitive notices.